NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
Clinical Trials
10 trialsNCT01532011 2016-07-04
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00126620 2015-07-23
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
University Health Network, Toronto
Phase 1 Completed
NCT00770263 2015-06-03
Erlotinib and Temsirolimus for Solid Tumors
Washington University School of Medicine
Phase 1 Completed
NCT00276575 2014-11-19
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00759928 2014-07-02
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00996515 2013-05-01
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00495872 2012-10-18
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00320073 2012-05-16
Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00137826 2011-12-26
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Completed